(Q46947501)

English

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

scientific article published in April 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

author name string

Branford S

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

Moore S

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

Hughes TP

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

publication date

1 April 2006

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

20

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

664-670

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404139

0 references

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

RE: Bain B.J. (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clinical and Laboratory Haematology26, 315-318.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Bone marrow biopsy morbidity and mortality: 2002 data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Clinical significance of Y chromosome loss in hematologic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic analysis of mosaicism in 53 women with Turner syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Extensive cytogenetic studies of clonality following interferon-alpha therapy in chronic myeloid leukemia occurring in monosomic cells in a patient with Turner syndrome mosaic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404139

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16482210

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46947501&oldid=1466088975"